Exclusive special offer and discount title banner vector image

CHRONIC KIDNEY DISEASE (CKD) PIPELINE INSIGHT 2024

SCOPE OF THE REPORT

Chronic kidney disease (CKD) Pipeline Therapeutic Assessment: Active Products (Evaluation by Route of Administration, Evaluation by Stage and Route of Administration, Evaluation by Molecule Type, Evaluation by Stage and Molecule Type, Evaluation by Product Type, Evaluation by Stage and Product Type)

REQUEST CUSTOMIZATION

MARKET OVERVIEW

Chronic kidney disease (CKD) is a progressive medical condition marked by a gradual decline in kidney function over time. The kidneys filter waste products and excess fluids from the blood. Impaired kidneys result in the accumulation of harmful substances and fluids in the body, causing significant health issues. Chronic kidney disease (CKD) varies in severity and typically worsens without proper management. 

Early diagnosis and treatment are vital for slowing disease progression and improving patient outcomes. Without intervention, CKD can advance to end-stage renal disease, requiring renal replacement therapy such as dialysis or kidney transplantation. Additionally, individuals with CKD have a higher risk of early-onset cardiovascular disease, highlighting the importance of timely and effective medical intervention.

Chronic Kidney Disease

Read our latest blog on the Chronic Kidney Disease (CKD) Market

GROWTH ENABLERS

Key growth enablers of the global chronic kidney disease (CKD) market: 

  • Early detection and precision medicine for chronic kidney disease
  • Growing incidence of chronic kidney disease
  • Rising research and development efforts
    • The growing prevalence of chronic kidney disease (CKD) and the limited availability of effective therapies are prompting an urgent need for innovative drug research and development. 
    • In essence, researchers are working to develop new therapies targeting CKD, with the goal of expanding the market for CKD treatments. The focus on research and development aims to address the unmet medical needs of CKD patients, ultimately improving patient outcomes and enhancing the overall quality of care for those affected by the disease.
    • Moving ahead, cutting-edge gene editing technologies, particularly CRISPR (clustered, regularly interspaced short palindromic repeats), are being explored for their potential in treating CKD. Unlike traditional gene therapy approaches, CRISPR allows for precise editing or repair of specific disease-causing mutations.

GROWTH RESTRAINTS

Key growth restraining factors of the global chronic kidney disease (CKD) market:

  • Limited patient awareness of the disease
  • Heightened risk of related comorbidities
  • Knowledge gap in chronic kidney disease treatment
    • One of the primary barriers to expanding CKD treatment is the widespread lack of understanding about the disease. Many patients are unaware of the severity of CKD and the risk factors contributing to its progression.
    • A major obstacle in the treatment and management of CKD is the lack of patient education regarding appropriate prevention and management strategies. This gap in knowledge, in turn, hinders effective disease management.
    • The success of CKD preventive and screening programs heavily relies on public awareness and understanding. Early detection and management are crucial for preventing disease progression. However, many CKD cases remain undetected in the early stages due to insufficient public knowledge.

To Know More About This Report, Request a Free Sample Copy

Chronic Kidney Disease (CKD) | Disease Overview

  • Introduction
  • Etiology and Risk Factors
    • Chronic kidney disease (CKD) is often caused by diabetes and high blood pressure, both of which can damage the nephrons in the kidneys. The kidneys’ extensive vascularization makes them susceptible to blood vessel diseases, raising the risk of heart attacks, strokes, and CKD. Furthermore, CKD can lead to high blood pressure, creating a vicious cycle.
    • Obstructed urine flow, caused by conditions such as an enlarged prostate, kidney stones, or tumors, can lead to CKD by increasing pressure on the kidneys. Other significant causes include kidney diseases like polycystic kidney disease, pyelonephritis, and glomerulonephritis. Additionally, kidney artery stenosis, fetal developmental problems, systemic lupus erythematosus, and the overuse of certain medications, such as non-steroidal anti-inflammatory drugs (NSAIDs), contribute to the development of CKD.
    • Several risk factors increase the likelihood of developing CKD, including a family history of kidney disease, being over 60, obesity, heart disease, previous kidney damage, abnormal kidney structure, and smoking. Managing these risk factors is crucial in preventing CKD.
  • Stages
  • Pathophysiology
  • Diagnosis
    • The primary diagnostic tool for CKD involves blood tests to assess kidney function. This includes measuring serum creatinine levels, a waste product indicative of kidney function. Elevated creatinine levels above 1.2 mg/dL in women and 1.4 mg/dL in men suggest impaired kidney function. Additionally, the estimated glomerular filtration rate (eGFR) is calculated based on creatinine levels, age, and gender. An eGFR below 60 mL/min/1.73m² for three months or more indicates potential CKD progression.
    • Urine tests are crucial for detecting early signs of kidney damage. They measure the presence of albumin, a protein that should not normally be present in urine. Elevated albumin levels, known as albuminuria, indicate kidney disease. The albumin-to-creatinine ratio (ACR) quantifies albumin levels relative to creatinine in urine samples. ACR values above 30 mg/g indicate abnormal albuminuria, with values exceeding 300 mg/g indicating severe kidney damage.
    • Moreover, additional diagnostic methods include imaging tests such as ultrasound or CT scans to visualize kidney structure and identify any obstructions. A kidney biopsy may be performed in cases where the underlying cause of CKD needs further clarification.
  • Treatment and Management

MAJOR PLAYERS

Major players in the global chronic kidney disease (CKD) market:

  • Eli Lilly and Company
  • ProKidney Corp
  • Boehringer Ingelheim
  • AstraZeneca Plc
  • Novo Nordisk

AstraZeneca Plc is a biopharmaceutical company specializing in the research, development, and commercialization of a wide range of prescription drugs. It focuses on respiratory, cardiovascular, renal, and metabolic diseases alongside cancer, autoimmune conditions, infections, and neurological disorders. Their diverse product portfolio includes biologics, prescription pharmaceuticals, and vaccines. The company distributes its products through wholly-owned local marketing subsidiaries, distributors, and regional offices, targeting primary care and specialty care physicians. Operating globally across Europe, the Americas, Asia, Africa, and Australasia, AstraZeneca is headquartered in Cambridge, United Kingdom.

Zibotentan is an experimental anti-cancer drug candidate in development by AstraZeneca. Dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, decreases the reabsorption of filtered glucose, promoting its excretion through urine. It also reduces sodium reabsorption and enhances sodium delivery to the distal tubule. Zibotentan, an orally available selective antagonist of the endothelin-A (ET-A) receptor, has potential as an antineoplastic agent. By blocking the activity of the Endothelin A receptor, it inhibits tumor growth and metastasis.

TABLE OF CONTENTS

  1. INTRODUCTION TO THE REPORT
  2. CHRONIC KIDNEY DISEASE: SUMMARY
  3. OVERVIEW
    1. INTRODUCTION
    2. ETIOLOGY AND RISK FACTORS
    3. STAGES
    4. PATHOPHYSIOLOGY
    5. DIAGNOSIS
    6. TREATMENT AND MANAGEMENT
  4. MARKET DYNAMICS
    1. KEY DRIVERS
      1. EARLY DETECTION AND PRECISION MEDICINE FOR CHRONIC KIDNEY DISEASE
      2. GROWING INCIDENCE OF CHRONIC KIDNEY DISEASE
      3. RISING RESEARCH AND DEVELOPMENT EFFORTS
    2. KEY RESTRAINTS
      1. LIMITED PATIENT AWARENESS OF THE DISEASE
      2. HEIGHTENED RISK OF RELATED COMORBIDITIES
      3. KNOWLEDGE GAP IN CHRONIC KIDNEY DISEASE TREATMENT
  5. PIPELINE THERAPEUTICS
    1. CURRENT PIPELINE OVERVIEW
    2. COMPARATIVE ANALYSIS: PRODUCTS IN VARIOUS PHASES
  6. THERAPEUTIC ASSESSMENT: ACTIVE PRODUCTS
    1. EVALUATION BY ROUTE OF ADMINISTRATION
    2. EVALUATION BY STAGE AND ROUTE OF ADMINISTRATION
    3. EVALUATION BY MOLECULE TYPE
    4. EVALUATION BY STAGE AND MOLECULE TYPE
    5. EVALUATION BY PRODUCT TYPE
    6. EVALUATION BY STAGE AND PRODUCT TYPE
  7. LATE-STAGE PRODUCTS (REGISTERED)
    1. COMPARATIVE ANALYSIS
    2. EMPAGLIFLOZIN: BOEHRINGER INGELHEIM/ELI LILLY AND COMPANY
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. PRODUCT DEVELOPMENTAL ACTIVITIES
  8. LATE-STAGE PRODUCTS (PRE-REGISTRATION)
    1. COMPARATIVE ANALYSIS
    2. BARDOXOLONE METHYL: REATA PHARMACEUTICALS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. PRODUCT AND DEVELOPMENTAL ACTIVITIES
  9. LATE-STAGE PRODUCTS (PHASE III)
    1. COMPARATIVE ANALYSIS
    2. KBP-5074: KBP BIOSCIENCES
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. SAFETY AND EFFICACY
      4. PRODUCT DEVELOPMENTAL ACTIVITIES
    3. ZILTIVEKIMAB: NOVO NORDISK
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. SAFETY AND EFFICACY
      4. PRODUCT DEVELOPMENTAL ACTIVITIES
    4. SEMAGLUTIDE: NOVO NORDISK
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    5. RENAL AUTOLOGOUS CELL THERAPY: PROKIDNEY
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. PRODUCT DEVELOPMENTAL ACTIVITIES
    6. HSK-21542: HAISCO PHARMACEUTICAL GROUP CO LTD
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. SAFETY AND EFFICACY
    7. FINERENONE: BAYER
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
  10. MID-STAGE PRODUCTS (PHASE II/III)
    1. COMPARATIVE ANALYSIS
    2. US-APR2020: KIBOW PHARMA
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. PRODUCT DEVELOPMENTAL ACTIVITIES
  11. MID-STAGE PRODUCTS (PHASE II)
    1. COMPARATIVE ANALYSIS
    2. ZIBOTENTAN: ASTRAZENECA
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    3. RUNCACIGUAT: BAYER
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    4. PIRFENIDONE: ROCHE
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    5. VERINURAD + ALLOPURINOL: ASTRAZENECA
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    6. XRX-008: XORTX THERAPEUTICS
      1. PRODUCT DESCRIPTION
      2. SAFETY AND EFFICACY
      3. PRODUCT AND DEVELOPMENTAL ACTIVITIES
    7. MC2-25: MC2 THERAPEUTICS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    8. AZD9977: ASTRAZENECA
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    9. DM199: DIAMEDICA THERAPEUTICS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. SAFETY AND EFFICACY
    10. ALLN-346: ALLENA PHARMACEUTICALS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. PRODUCT DEVELOPMENTAL ACTIVITIES
    11. BI-685509: BOEHRINGER INGELHEIM
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    12. BI 764198: BOEHRINGER INGELHEIM
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    13. SCO-792: SCOHIA PHARMA
      1. PRODUCT DESCRIPTION
      2. SAFETY AND EFFICACY
      3. PRODUCT DEVELOPMENTAL ACTIVITIES
    14. BAXDROSTAT: CINCOR PHARMA
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. PRODUCT DEVELOPMENTAL ACTIVITIES
    15. GLPG2737: GALAPAGOS NV
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    16. BI 690517: BOEHRINGER INGELHEIM
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
  12. MID-STAGE PRODUCTS (PHASE I/II)
    1. COMPARATIVE ANALYSIS
    2. SBI-101: SENTIEN BIOTECHNOLOGIES INC
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    3. REGN5459: REGENERON PHARMACEUTICALS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    4. ELIXCYTE: UNICOCELL BIOMED
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. SAFETY AND EFFICACY
  13. EARLY-STAGE PRODUCTS (PHASE I)
    1. COMPARATIVE ANALYSIS
    2. RGLS8429: REGULUS THERAPEUTICS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. SAFETY AND EFFICACY
    3. JNJ-0237: JOHNSON & JOHNSON
      1. PRODUCT DESCRIPTION
    4. PXL770: POXEL SA
      1. PRODUCT DESCRIPTION
      2. PRODUCT AND DEVELOPMENTAL ACTIVITIES
    5. AL-01211: ACELINK THERAPEUTICS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    6. FT011: OCCURX
      1. PRODUCT DESCRIPTION
      2. SAFETY AND EFFICACY
      3. PRODUCT DEVELOPMENTAL ACTIVITIES
    7. CELLGRAM-CKD: PHARMICELL CO LTD
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. PRODUCT DEVELOPMENTAL ACTIVITIES
    8. CLBS201: LISATA THERAPEUTICS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. PRODUCT DEVELOPMENTAL ACTIVITIES
    9. BAY3283142: BAYER
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    10. ION532: IONIS PHARMACEUTICALS
      1. PRODUCT DESCRIPTION
      2. PRODUCT DEVELOPMENTAL ACTIVITIES
    11. MK-2060: MERCK SHARP & DOHME
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. PRODUCT DEVELOPMENTAL ACTIVITIES
    12. DISC-0974: DISC MEDICINE
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. PRODUCT DEVELOPMENTAL ACTIVITIES
    13. HRS-1780: SHANDONG SUNCADIA MEDICINE
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
    14. OCX063: OCCURX
      1. PRODUCT DESCRIPTION
      2. PRODUCT DEVELOPMENTAL ACTIVITIES
    15. AR882: ARTHROSI THERAPEUTICS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. SAFETY AND EFFICACY
    16. MTX652: MISSION THERAPEUTICS
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
      3. SAFETY AND EFFICACY
      4. PRODUCT DEVELOPMENTAL ACTIVITIES
    17. SSS17: SHENYANG SUNSHINE PHARMACEUTICAL
      1. PRODUCT DESCRIPTION
      2. RESEARCH AND DEVELOPMENT
  14. PRECLINICAL-STAGE PRODUCTS
    1. COMPARATIVE ANALYSIS
  15. DISCOVERY-STAGE PRODUCTS
    1. COMPARATIVE ANALYSIS
  16. UNKNOWN-STAGE PRODUCTS
    1. COMPARATIVE ANALYSIS
  17. INACTIVE-STAGE PRODUCTS
    1. COMPARATIVE ANALYSIS
  18. STRATEGIC DEVELOPMENTS 
    1. MERGERS & ACQUISITIONS
    2. PARTNERSHIPS & AGREEMENTS
    3. INVESTMENTS
  19. UNMET NEEDS

LIST OF TABLES

TABLE 1: TOTAL ACTIVE PRODUCTS IN CHRONIC KIDNEY DISEASE PIPELINE

TABLE 2: PRODUCTS IN VARIOUS PHASES 

TABLE 3: EVALUATION BY ROUTE OF ADMINISTRATION

TABLE 4: EVALUATION BY MOLECULE TYPE

TABLE 5: EVALUATION BY PRODUCT TYPE

TABLE 6: LATE-STAGE PRODUCTS (REGISTERED)

TABLE 7: CLINICAL TRIALS DESCRIPTION: EMPAGLIFLOZIN

TABLE 8: GENERAL DESCRIPTION: EMPAGLIFLOZIN

TABLE 9: LATE-STAGE PRODUCTS (PRE-REGISTRATION)

TABLE 10: CLINICAL TRIALS DESCRIPTION: BARDOXOLONE METHYL

TABLE 11: GENERAL DESCRIPTION: BARDOXOLONE METHYL

TABLE 12: LATE-STAGE PRODUCTS (PHASE III)

TABLE 13: CLINICAL TRIALS DESCRIPTION: KBP-5074

TABLE 14: GENERAL DESCRIPTION: KBP-5074

TABLE 15: CLINICAL TRIALS DESCRIPTION: ZILTIVEKIMAB

TABLE 16: GENERAL DESCRIPTION: ZILTIVEKIMAB

TABLE 17: CLINICAL TRIALS DESCRIPTION: SEMAGLUTIDE

TABLE 18: GENERAL DESCRIPTION: SEMAGLUTIDE

TABLE 19: CLINICAL TRIALS DESCRIPTION: RENAL AUTOLOGOUS CELL THERAPY

TABLE 20: GENERAL DESCRIPTION: RENAL AUTOLOGOUS CELL THERAPY

TABLE 21: CLINICAL TRIALS DESCRIPTION: HSK21542

TABLE 22: GENERAL DESCRIPTION: HSK-21542

TABLE 23: CLINICAL TRIALS DESCRIPTION: FINERENONE

TABLE 24: GENERAL DESCRIPTION: FINERENONE

TABLE 25: MID-STAGE PRODUCTS (PHASE II/III)

TABLE 26: CLINICAL TRIALS DESCRIPTION: ZIBOTENTAN

TABLE 27: GENERAL DESCRIPTION: US-APR2020

TABLE 28: MID-STAGE PRODUCTS (PHASE II)

TABLE 29: CLINICAL TRIALS DESCRIPTION: ZIBOTENTAN

TABLE 30: GENERAL DESCRIPTION: ZIBOTENTAN

TABLE 31: CLINICAL TRIALS DESCRIPTION: RUNCACIGUAT

TABLE 32: GENERAL DESCRIPTION: RUNCACIGUAT

TABLE 33: CLINICAL TRIALS DESCRIPTION: PIRFENIDONE

TABLE 34: GENERAL DESCRIPTION: PIRFENIDONE

TABLE 35: CLINICAL TRIALS DESCRIPTION: VERINURAD

TABLE 36: GENERAL DESCRIPTION: VERINURAD + ALLOPURINOL

TABLE 37: GENERAL DESCRIPTION: XRX-008

TABLE 38: CLINICAL TRIALS DESCRIPTION: MC2-25

TABLE 39: GENERAL DESCRIPTION: MC2-25

TABLE 40: CLINICAL TRIALS DESCRIPTION: AZD9977

TABLE 41: GENERAL DESCRIPTION: AZD9977

TABLE 42: CLINICAL TRIALS DESCRIPTION: DM199

TABLE 43: GENERAL DESCRIPTION: DM199

TABLE 44: CLINICAL TRIALS DESCRIPTION: ALLN-346

TABLE 45: GENERAL DESCRIPTION: ALLN-346

TABLE 46: CLINICAL TRIALS DESCRIPTION: BI-685509

TABLE 47: GENERAL DESCRIPTION: BI-685509

TABLE 48: CLINICAL TRIALS DESCRIPTION: BI 764198

TABLE 49: GENERAL DESCRIPTION: BI 764198

TABLE 50: GENERAL DESCRIPTION: SCO-792

TABLE 51: CLINICAL TRIALS DESCRIPTION: BAXDROSTAT

TABLE 52: GENERAL DESCRIPTION: BAXDROSTAT

TABLE 53: CLINICAL TRIALS DESCRIPTION: GLPG2737

TABLE 54: GENERAL DESCRIPTION: GLPG2737

TABLE 55: CLINICAL TRIALS DESCRIPTION: BI 690517

TABLE 56: GENERAL DESCRIPTION: BI 690517

TABLE 57: MID-STAGE PRODUCTS (PHASE I/II)

TABLE 58: CLINICAL TRIALS DESCRIPTION: SBI-101

TABLE 59: GENERAL DESCRIPTION: SBI-101

TABLE 60: CLINICAL TRIALS DESCRIPTION: REGN5459

TABLE 61: GENERAL DESCRIPTION: REGN5459

TABLE 62: CLINICAL TRIALS DESCRIPTION: ELIXCYTE

TABLE 63: GENERAL DESCRIPTION: ELIXCYTE

TABLE 64: EARLY-STAGE PRODUCTS (PHASE I)

TABLE 65: CLINICAL TRIALS DESCRIPTION: RGLS8429

TABLE 66: GENERAL DESCRIPTION: RGLS8429

TABLE 67: GENERAL DESCRIPTION: JNJ-0237

TABLE 68: GENERAL DESCRIPTION: PXL770

TABLE 69: CLINICAL TRIALS DESCRIPTION: AL-01211

TABLE 70: GENERAL DESCRIPTION: AL-01211

TABLE 71: GENERAL DESCRIPTION: FT011

TABLE 72: CLINICAL TRIALS DESCRIPTION: CELLGRAM-CKD

TABLE 73: GENERAL DESCRIPTION: CELLGRAM-CKD

TABLE 74: CLINICAL TRIALS DESCRIPTION: CLBS201

TABLE 75: GENERAL DESCRIPTION: CLBS201

TABLE 76: CLINICAL TRIALS DESCRIPTION: BAY3283142

TABLE 77: GENERAL DESCRIPTION: BAY3283142

TABLE 78: GENERAL DESCRIPTION: ION532

TABLE 79: CLINICAL TRIALS DESCRIPTION: MK-2060

TABLE 80: GENERAL DESCRIPTION: MK-2060

TABLE 81: CLINICAL TRIALS DESCRIPTION: DISC-0974

TABLE 82: GENERAL DESCRIPTION: DISC-0974

TABLE 83: CLINICAL TRIALS DESCRIPTION: HRS-1780

TABLE 84: GENERAL DESCRIPTION: HRS-1780

TABLE 85: GENERAL DESCRIPTION: OCX063

TABLE 86: CLINICAL TRIALS DESCRIPTION: AR882

TABLE 87: GENERAL DESCRIPTION: AR882

TABLE 88: GENERAL DESCRIPTION: MTX652

TABLE 89: CLINICAL TRIALS DESCRIPTION: SSS17

TABLE 90: GENERAL DESCRIPTION: SSS17

TABLE 91: PRECLINICAL-STAGE PRODUCTS

TABLE 92: DISCOVERY-STAGE PRODUCTS

TABLE 93: UNKNOWN-STAGE PRODUCTS

TABLE 94: INACTIVE-STAGE PRODUCTS

TABLE 95: LIST OF MERGERS & ACQUISITIONS

TABLE 96: LIST OF PARTNERSHIPS & AGREEMENTS

TABLE 97: LIST OF INVESTMENTS

LIST OF FIGURES 

FIGURE 1: STAGES OF CHRONIC KIDNEY DISEASE

FIGURE 2: PATHOPHYSIOLOGY OF MODERATE TO SEVERE CHRONIC KIDNEY DISEASE

FIGURE 3: PRODUCTS IN VARIOUS PHASES

FIGURE 4: EVALUATION BY ROUTE OF ADMINISTRATION

FIGURE 5: EVALUATION BY STAGE AND ROUTE OF ADMINISTRATION

FIGURE 6: EVALUATION BY MOLECULE TYPE

FIGURE 7: EVALUATION BY STAGE AND MOLECULE TYPE

FIGURE 8: EVALUATION BY PRODUCT TYPE

FIGURE 9: EVALUATION BY STAGE AND PRODUCT TYPE

FIGURE 10: LATE-STAGE PRODUCTS (REGISTERED)

FIGURE 11: LATE-STAGE PRODUCTS (PRE-REGISTRATION)

FIGURE 12: LATE-STAGE PRODUCTS (PHASE III)

FIGURE 13: MID-STAGE PRODUCTS (PHASE II/III)

FIGURE 14: MID-STAGE PRODUCTS (PHASE II)

FIGURE 15: MID-STAGE PRODUCTS (PHASE I/II)

FIGURE 16: EARLY-STAGE PRODUCTS (PHASE I)

FIGURE 17: PRECLINICAL-STAGE PRODUCTS

FIGURE 18: DISCOVERY-STAGE PRODUCTS

FIGURE 19: UNKNOWN-STAGE PRODUCTS

FIGURE 20: INACTIVE-STAGE PRODUCTS

FAQ’s

FAQs

Chronic kidney disease (CKD) may lead to complications such as cardiovascular disease, anemia, bone disease, electrolyte imbalances, and fluid retention. These complications can worsen as CKD progresses to end-stage renal disease (ESRD).

In the early stages, CKD may not cause noticeable symptoms. As it progresses, symptoms may include fatigue, swelling in the ankles, decreased urine output, difficulty concentrating, and blood in the urine.

CKD diagnosis involves blood tests to measure creatinine levels and estimate the glomerular filtration rate (eGFR), as well as urine tests to check for protein levels (albuminuria). Imaging tests such as ultrasounds or CT scans may also be used, and in some cases, a kidney biopsy is performed.

Request Customization
Request Customization
Request free sample